114 related articles for article (PubMed ID: 28709933)
1. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma.
Lai X; Umbricht CB; Fisher K; Bishop J; Shi Q; Chen S
J Proteomics; 2017 Aug; 166():59-67. PubMed ID: 28709933
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma.
Lai X; Chen S
Cancer Genomics Proteomics; 2015; 12(6):271-81. PubMed ID: 26543076
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland.
Rickert D; Mittermayer C; Lindenfelser R; Biesterfeld S
Anal Quant Cytol Histol; 2000 Jun; 22(3):229-34. PubMed ID: 10872040
[TBL] [Abstract][Full Text] [Related]
4. Proteomic identification of new biomarkers and application in thyroid cytology.
Torres-Cabala C; Bibbo M; Panizo-Santos A; Barazi H; Krutzsch H; Roberts DD; Merino MJ
Acta Cytol; 2006; 50(5):518-28. PubMed ID: 17017437
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
7. [Approach to thyroid incidentaloma and follicular adenoma].
Tajiri J
Nihon Rinsho; 2007 Nov; 65(11):2099-105. PubMed ID: 18018577
[TBL] [Abstract][Full Text] [Related]
8. [HBME-1 and cyclin D1 as diagnostic markers for follicular thyroid carcinoma].
Moyano L; Franco C; Carreño L; Robinson P; Sánchez G
Rev Med Chil; 2004 Mar; 132(3):279-84. PubMed ID: 15376563
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.
Umbricht CB; Saji M; Westra WH; Udelsman R; Zeiger MA; Sukumar S
Cancer Res; 1997 Jun; 57(11):2144-7. PubMed ID: 9187112
[TBL] [Abstract][Full Text] [Related]
12. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
13. [Follicular thyroid tumor as a diagnostic and therapeutic problem].
Król R; Heitzman M; Pawlicki J; Ziaja J; Cierpka L
Postepy Hig Med Dosw (Online); 2004; 58():490-4. PubMed ID: 15765010
[TBL] [Abstract][Full Text] [Related]
14. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma.
Lai X; Chen S
Proteomics; 2015 Jul; 15(13):2358-68. PubMed ID: 25755173
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
Haghpanah V; Shooshtarizadeh P; Heshmat R; Larijani B; Tavangar SM
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):422-5. PubMed ID: 17122639
[TBL] [Abstract][Full Text] [Related]
17. Detection of metabolites discriminating subtypes of thyroid cancer: Molecular profiling of FFPE samples using the GC/MS approach.
Wojakowska A; Chekan M; Marczak Ł; Polanski K; Lange D; Pietrowska M; Widlak P
Mol Cell Endocrinol; 2015 Dec; 417():149-57. PubMed ID: 26415588
[TBL] [Abstract][Full Text] [Related]
18. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling of follicular and papillary thyroid tumors.
Sofiadis A; Becker S; Hellman U; Hultin-Rosenberg L; Dinets A; Hulchiy M; Zedenius J; Wallin G; Foukakis T; Höög A; Auer G; Lehtiö J; Larsson C
Eur J Endocrinol; 2012 Apr; 166(4):657-67. PubMed ID: 22275472
[TBL] [Abstract][Full Text] [Related]
20. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
